BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 26345553)

  • 21. Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN.
    Jutzi JS; Mullally A
    Front Immunol; 2020; 11():2093. PubMed ID: 32983162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Bone marrow histology in leukemia and related conditions].
    Marton PF
    Tidsskr Nor Laegeforen; 1974 Nov; 94(32):2223-5. PubMed ID: 4612870
    [No Abstract]   [Full Text] [Related]  

  • 24. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
    Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
    Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
    Hall J; Foucar K
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
    Găman M; Vlădăreanu AM; Radesi S
    Rom J Intern Med; 2011; 49(1):25-30. PubMed ID: 22026249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone marrow in megakaryocytic disorders.
    Burkhardt R
    Hematol Oncol Clin North Am; 1988 Dec; 2(4):695-733. PubMed ID: 3065325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K; Bock O; Kreipe H
    Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Significance of bone marrow cytology in the diagnosis of leukosis in dogs].
    Moritz A; Grünbaum EG
    Tierarztl Prax; 1993 Jun; 21(3):243-51. PubMed ID: 8346528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Myeloproliferative disorders].
    Binder D; Fehr J
    Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Histomorphologic findings of the bone marrow in chronic myeloproliferative diseases].
    Thiele J; Fischer R
    Z Hautkr; 1989 Oct; 64(10):903-4, 909-12. PubMed ID: 2686247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 34. Role of inflammation in the biology of myeloproliferative neoplasms.
    Koschmieder S; Chatain N
    Blood Rev; 2020 Jul; 42():100711. PubMed ID: 32505517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative interpretation of bone marrow biopsies in MPN-What's the point in a molecular age?
    Ryou H; Lomas O; Theissen H; Thomas E; Rittscher J; Royston D
    Br J Haematol; 2023 Nov; 203(4):523-535. PubMed ID: 37858962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Hen or the Egg: Inflammatory Aspects of Murine MPN Models.
    Jutzi JS; Pahl HL
    Mediators Inflamm; 2015; 2015():101987. PubMed ID: 26543325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why?
    Cumbo C; Anelli L; Zagaria A; Coccaro N; Tarantini F; Specchia G; Musto P; Albano F
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Bone marrow pathology of myeloproliferative neoplasms].
    Ito M
    Rinsho Ketsueki; 2015 Aug; 56(8):956-62. PubMed ID: 26345553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.